Back

What is the evidence for empagliflozin in HFpEF?

27 August 2022 (12:50 - 13:00)
Organised by:
Congress Presentation Part of: SGLT2 inhibitors in practice (part 2): how do we implement new treatments in HFpEF? Heart Failure with Preserved Ejection Fraction (HFpEF) Open Access ESC Congress 2022

About the speaker

Photo
Professor Giuseppe Rosano

St Georges Medical School, London (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
Introduction and recap.
Professor S. Anker (Berlin, DE)
Slides Video
Presentation thumbnail
Implementing empagliflozin for HFpEF treatment in my practice.
Professor M. Boehm (Homburg, DE)
Slides Video
Presentation thumbnail
Panel discussion.
Professor S. Anker (Berlin, DE)
Slides Video

Access the full session

Session thumbnail
SGLT2 inhibitors in practice (part 2): how do we implement new treatments in HFpEF?
Video

The Event

Event poster

ESC Congress 2022

27 August 2022 12:50 CET
You may be interested in
thumbnail
Congress Session
Practical guidance to implement heart failure treatment with SGLT2 inhibitors in the outpatient setting
thumbnail
Congress Session
New perspectives for the treatment of chronic heart failure
thumbnail
Congress Presentation
Audience Q&A

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources